Brain Tumor Investment Fund

The Brain Tumor Investment Fund (BTIF) operates as a venture philanthropy fund, strategically deploying capital into biotechnology, pharmaceutical, and medical device companies. Associated with the National Brain Tumor Society, BTIF targets early-stage innovations aimed at developing novel therapies and technologies for brain tumor patients. Its unique approach leverages philanthropic donations to catalyze private sector investment, fostering a more robust market for drug development in neuro-oncology.

John Higgins serves as the Managing Director of the fund, which launched in 2019. The foundational insight behind BTIF stemmed from recognizing a critical gap between promising scientific discoveries originating in academic institutions and their subsequent commercial development. By directly investing in companies with high-potential brain tumor assets, BTIF seeks to accelerate the translation of research into tangible patient solutions, drawing on decades of specialized knowledge from its parent organization.

BTIF's indirect beneficiaries are brain tumor patients globally, through the companies it supports that are developing life-changing products. The fund's overarching vision is to contribute significantly to the conquest and cure of brain tumors by driving innovation and ensuring promising treatments reach clinical stages. It works to cultivate an environment where groundbreaking research is effectively commercialized, ultimately improving patient outcomes and transforming the landscape of brain tumor care.